STOCK TITAN

Blueprint Medicines to Report Third Quarter 2023 Financial Results on Thursday, October 26, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
Blueprint Medicines Corporation to report Q3 financial results and provide corporate update.
Positive
  • Blueprint Medicines Corporation will host a live conference call and webcast on October 26, 2023, to report its third quarter financial results and provide a corporate update.
Negative
  • None.

CAMBRIDGE, Mass., Oct. 12, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, October 26, 2023, to report its third quarter financial results and provide a corporate update.

To access the live conference call, please dial 833-470-1428 (domestic) or 404-975-4839 (international), and refer to conference ID 368229. A webcast of the call will also be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at http://ir.blueprintmedicines.com/. The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call.

About Blueprint Medicines

Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate our scientific innovation into a broad pipeline of important approved and investigational precision therapies aimed at addressing difficult-to-treat cancers and blood disorders. Today, we are delivering our approved medicines to patients in the United States, Europe, and in other geographies ourselves or through our partners. In addition, we are globally advancing multiple programs for systemic mastocytosis, lung cancer, breast cancer, and other genomically defined cancers, and cancer immunotherapy. For more information, visit www.BlueprintMedicines.com and follow us on Twitter (@BlueprintMeds) and LinkedIn.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-to-report-third-quarter-2023-financial-results-on-thursday-october-26-2023-301954149.html

SOURCE Blueprint Medicines Corporation

FAQ

When will Blueprint Medicines Corporation report its Q3 financial results?

Blueprint Medicines Corporation will report its Q3 financial results on October 26, 2023.

Where can I access the live conference call and webcast?

You can access the live conference call by dialing 833-470-1428 (domestic) or 404-975-4839 (international), and refer to conference ID 368229. The webcast will also be available on the Blueprint Medicines website at http://ir.blueprintmedicines.com/.

How long will the archived webcast be available?

The archived webcast will be available on Blueprint Medicines' website for 30 days following the call.

Blueprint Medicines Corporation

NASDAQ:BPMC

BPMC Rankings

BPMC Latest News

BPMC Stock Data

6.65B
60.55M
0.85%
108.07%
7.14%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
CAMBRIDGE

About BPMC

blueprint medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. we are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. by focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. we see a substantial opportunity in kinase drug discovery and development